Samsung Biologics Plant 3 (Image courtesy of Samsung Bioilogics)
SEOUL, Dec. 18 (Korea Bizwire) – Samsung Biologics announced on December 18 that it will invest in U.S.-based biotech company Generate Biomedicines through the Samsung Life Science Fund, a venture fund established to advance life sciences innovation.
The Samsung Life Science Fund, jointly capitalized with KRW 240 billion ($167 million) by Samsung Biologics, Samsung C&T [028260], and Samsung Bioepis, is managed by Samsung Ventures.
Generate Biomedicines specializes in protein design using generative artificial intelligence (AI) and machine learning. The company’s proprietary AI platform enables the rapid creation of de novo proteins—entirely novel proteins not based on existing sequences or structures—tailored to specific functions, significantly reducing drug development timelines.
Samsung Biologics emphasized that this investment positions Samsung at the forefront of innovative biotech ventures, with plans to support the commercialization of novel therapeutics.
The partnership also lays the groundwork for strategic collaborations, such as contract manufacturing (CMO) and joint development, leveraging AI-based technologies to expand Samsung’s presence in the life sciences sector.
The move underscores Samsung’s commitment to fostering cutting-edge advancements in biopharmaceuticals and building a robust ecosystem for AI-driven drug development.
* Note to editor: The KRW-to-USD exchange rate referenced in the article is based on the rate applicable on the date of publication.
Ashley Song (ashley@koreabizwire.com)
